Methods for assessing risk of developing a viral disease using a genetic test
Eli Hatchwell, Winchester (GB); Peggy S. Eis, Fitchburg, WI (US); Edward B. Smith, III, New York, NY (US); and Yassine Taoufik, Paris (FR)
Assigned to PML Screening, LLC, Newport Beach, CA (US); The Université Paris-Saclay, Saint Aubin (FR); The Assistance Publique—Hôpitaux de Paris (APHP), Paris (FR); and The Institut National de la Santé et de la Recherche Médicale (INSERM), Paris (FR)
Filed by PML Screening, LLC, Newport Beach, CA (US); The Université Paris-Saclay, Saint Aubin (FR); The Assistance Publique—Hôpitaux de Paris (APHP), Paris (FR); and The Institut National de la Santé et de la Recherche Médicale (INSERM), Paris (FR)
Filed on Mar. 16, 2023, as Appl. No. 18/185,153.
Application 18/185,153 is a division of application No. 17/141,885, filed on Jan. 5, 2021.
Application 17/141,885 is a division of application No. 16/245,849, filed on Jan. 11, 2019, granted, now 10,941,448, issued on Mar. 9, 2021.
Application 16/245,849 is a continuation of application No. 15/639,591, filed on Jun. 30, 2017, granted, now 10,240,205, issued on Mar. 26, 2019.
Claims priority of provisional application 62/524,324, filed on Jun. 23, 2017.
Claims priority of provisional application 62/454,676, filed on Feb. 3, 2017.
Prior Publication US 2023/0265519 A1, Aug. 24, 2023
1. A method of treating a condition in a subject in need of belimumab comprising: administering a therapeutically effective amount of belimumab to the subject, wherein the subject has a decreased risk of progressive multifocal leukoencephalopathy (PML) due to an infection of the brain by John Cunningham virus (JCV), wherein the subject's decreased risk is associated with the absence of one or more genetic variations in the subject, wherein the subject has been tested for a presence of the one or more genetic variations with a genetic assay and has been identified as not having the one or more genetic variations; wherein the one or more genetic variations comprise a single nucleotide variation (SNV) in a syntaxin binding protein 2 (STXBP2) gene, wherein the SNV in a STXBP2 gene comprises chr19:7712287 G>C; wherein chromosome positions of the one or more genetic variations are defined with respect to UCSC hg19.